Home/Pipeline/ADCT-901

ADCT-901

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

ADC Therapeutics

About ADC Therapeutics

ADC Therapeutics is a commercial-stage oncology company with a mission to transform cancer treatment through its proprietary ADC platform. Its key achievement is the FDA approval and commercialization of ZYNLONTA® for relapsed/refractory large B-cell lymphoma, establishing a revenue base. The company's strategy is to maximize ZYNLONTA's potential through label expansion while leveraging its differentiated linker/payload technology to advance a focused pipeline in high-need oncology indications.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active